FDAapproval95% confidence
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Incyte; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Hematology · JAK Inhibitor
- Sub-indication
- General
Related signal: FDA Approves JAKAFI XR (Ruxolitinib Phosphate) Submission by Incyte